Whole-body Magnetische Resonantie Voor Het Opsporen Van Bot- en Weke Delenmetastasen Bij patiënten Met Een Borstcarcinoom (MetaMaRBo)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Validation of whole body diffusion weighted MRI in breastcancer patients
- Last Updated
- 13 years ago
Overview
Brief Summary
Prospective MR-imaging study : role of magnetic resonance (MR) and Diffusion weighted imaging (DWI) MR in staging and therapy assessment in breast cancer patients with bone metastases.
Detailed Description
About 50 patients with a proven breast cancer and bone metastases will be included. First step : staging * nuclear bone scan * Positron Emission Tomography (PET/CT) * MR (whole body short tau inversion recovery (STIR)-sequence and T1-sequence and Diffusion weighted imaging (DWI),no contrast administration Aim : * Validation of whole body diffusion weighted imaging in detection of bone metastases and visceral metastases, comparing to Bone scan en PET/CT results. * To calculate cut-off values for DWI for bone and visceral metastases. Second step : therapy follow-up/therapy assessment. * Two groups of patients (oncologist takes the decision about therapy) 1. Patients treated by chemotherapy 2. Patients treated by hormonal therapy * on week 3, 12-16 and 52 in the chemotherapy or hormonal therapy-setting, a whole body MR (same protocol, no contrast) will be performed. End-point: Whole body MR with DWI is useful and reliable to assess the treatment response.
Investigators
Steven Pans
Medical Doctor radiologist
Universitaire Ziekenhuizen KU Leuven
Eligibility Criteria
Inclusion Criteria
- •Patients with a proven breast cancer (by biopsy or imaging)
- •Bone metastases proven by MR, PET-CT or Bone. Patients with visceral metastases can be included if bone metastases are also present.
- •Patient with an informed consent.
Exclusion Criteria
- •Patients with a single bone metastasis treated by Radiotherapy will be excluded.
- •Patients with contra-indication for MRI: pacemaker, cochlear implant, non MR compatible devices (Baclofenpump).
- •Claustrophobia
- •Patient in a bad general condition.
Outcomes
Primary Outcomes
Validation of whole body diffusion weighted MRI in breastcancer patients
Time Frame: 6 months
whole body MRI will be correlated to the nucleair bone scan and PET-CT
Secondary Outcomes
- Whole body MRI with diffusion weighted imaging is a reliable imaging tool for therapy assessment(12 months)